Impel Neuropharma Inc (IMPL)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
CEO:
Adrian Adams
Employees:
130
201 ELLIOTT AVE. W, SUITE 260, SEATTLE, WA 98119
206-568-1466

Impel NeuroPharma, Inc. focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is TRUDHESA, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine.

Data derived from most recent annual or quarterly report
Market Cap 201.625 Million Shares Outstanding23.175 Million Avg 30-day Volume 29.565 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-15.56
Price to Revenue60.8267 Debt to Equity1.7141 EBITDA-85.984 Million
Price to Book Value5.3717 Operating Margin-3475.0721 Enterprise Value64.895 Million
Current Ratio5.929 EPS Growth1.11 Quick Ratio5.576
1 Yr BETA 1.0456 52-week High/Low 34.75 / 5.72 Profit Margin-3799.5468
Operating Cash Flow Growth-109.7265 Altman Z-Score-2.5445 Free Cash Flow to Firm -16.867 Million
Earnings Report2022-08-15
View SEC Filings from IMPL instead.

View recent insider trading info

Funds Holding IMPL (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding IMPL

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

PARKER H STEWART

  • Director
12,789 2022-06-16 1

NELSON TIMOTHY S

  • Director
12,789 2022-06-16 2

SHAH MAHENDRA

  • Director
12,789 2022-06-16 1

WILFONG DIANE E.

  • Director
12,789 2022-06-16 1

ALLISON DAVID D.

  • Director
12,789 2022-06-16 1

SHREWSBURY STEPHEN B CHIEF MEDICAL OFFICER

  • Officer
97,990 2022-03-29 3

ADAMS ADRIAN COB, CEO AND PRESIDENT

  • Officer
  • Director
175,000 2022-01-26 2

LEAMAN JOHN HAROLD CHIEF FIN. & BUSINESS OFFICER

  • Officer
100,000 2022-01-26 2

PAOLILLO LEONARD CHIEF COMMERCIAL OFFICER

  • Officer
40,000 2022-01-26 1

HOEKMAN JOHN CHIEF SCIENTIFIC OFFICER

  • Officer
35,000 2022-01-26 2

KKR IRIS INVESTORS LLC

KKR HEALTHCARE STRATEGIC GROWTH FUND L.P.

KKR ASSOCIATES HCSG L.P.

KKR HCSG GP LLC

KKR GROUP PARTNERSHIP L.P.

KKR GROUP HOLDINGS CORP.

KKR & CO. INC.

KKR MANAGEMENT LLP

KRAVIS HENRY R

ROBERTS GEORGE R

3,802,638 2021-04-27 0

NORWEST VENTURE PARTNERS XIV, LP

CROWE JEFFREY

HAQUE PROMOD

KOSSOW JON ERIK

  • 10% Owner
3,077,198 2021-04-27 0

5AM VENTURES V, L.P.

5AM PARTNERS V, LLC

PARMAR KUSH

ROCKLAGE SCOTT M

SCHWAB ANDREW J.

5AM OPPORTUNITIES I, L.P.

5AM OPPORTUNITIES I (GP), LLC

  • 10% Owner
2,884,791 2021-04-27 0

VENBIO GLOBAL STRATEGIC FUND II L.P.

VENBIO GLOBAL STRATEGIC GP II, L.P.

VENBIO GLOBAL STRATEGIC GP II, LTD.

GOODMAN COREY S

ADELMAN ROBERT J

2,759,791 2021-04-27 0

VIVO CAPITAL VIII, LLC

VIVO CAPITAL FUND VIII, L.P.

VIVO CAPITAL SURPLUS FUND VIII, L.P.

  • 10% Owner
2,884,789 2021-04-27 0

5AM VENTURES V, L.P.

5AM PARTNERS V, LLC

PARMAR KUSH

ROCKLAGE SCOTT M

SCHWAB ANDREW J.

  • 10% Owner
1,359,799 2021-04-22 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
IMPEL PHARMACEUTICALS INC IMPL 2022-08-15 22:15:04 UTC -35.8735 38.1935 70000
IMPEL PHARMACEUTICALS INC IMPL 2022-08-15 21:45:04 UTC -35.8735 38.1935 70000
IMPEL PHARMACEUTICALS INC IMPL 2022-08-15 21:15:04 UTC -35.8735 38.1935 70000
IMPEL PHARMACEUTICALS INC IMPL 2022-08-15 20:45:04 UTC -35.8735 38.1935 70000
IMPEL PHARMACEUTICALS INC IMPL 2022-08-15 20:15:03 UTC -35.8735 38.1935 70000
IMPEL PHARMACEUTICALS INC IMPL 2022-08-15 19:45:04 UTC -35.8735 38.1935 70000
IMPEL PHARMACEUTICALS INC IMPL 2022-08-15 19:15:04 UTC -35.8735 38.1935 70000
IMPEL PHARMACEUTICALS INC IMPL 2022-08-15 18:45:04 UTC -35.8735 38.1935 70000
IMPEL PHARMACEUTICALS INC IMPL 2022-08-15 18:15:04 UTC -35.8735 38.1935 70000
IMPEL PHARMACEUTICALS INC IMPL 2022-08-15 17:45:04 UTC -35.8735 38.1935 70000
IMPEL PHARMACEUTICALS INC IMPL 2022-08-15 17:15:03 UTC -35.8735 38.1935 70000
IMPEL PHARMACEUTICALS INC IMPL 2022-08-15 16:45:04 UTC -35.6633 37.9833 70000
IMPEL PHARMACEUTICALS INC IMPL 2022-08-15 16:15:04 UTC -35.6633 37.9833 70000
IMPEL PHARMACEUTICALS INC IMPL 2022-08-15 15:45:04 UTC -35.6633 37.9833 60000
IMPEL PHARMACEUTICALS INC IMPL 2022-08-15 15:15:04 UTC -35.6633 37.9833 60000
IMPEL PHARMACEUTICALS INC IMPL 2022-08-15 14:45:04 UTC -35.6633 37.9833 60000
IMPEL PHARMACEUTICALS INC IMPL 2022-08-15 14:15:03 UTC -35.6633 37.9833 60000
IMPEL PHARMACEUTICALS INC IMPL 2022-08-15 13:45:04 UTC -31.8605 34.1805 60000
IMPEL PHARMACEUTICALS INC IMPL 2022-08-15 13:15:04 UTC -31.8605 34.1805 55000
IMPEL PHARMACEUTICALS INC IMPL 2022-08-15 12:45:04 UTC -31.8605 34.1805 55000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments